Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib In Treatment Of Metastatic Castrate Refractory Prostate Cancer
26/06/2023 17:15
June 26 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN
PATENT
COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE
REFRACTORY PROSTATE CANCER (MCRPC)
* THIS NEW EUROPEAN PATENT PROVIDES INTELLECTUAL PROPERTY
PROTECTION FOR MASITINIB IN TREATMENT OF MCRPC UNTIL 2042
Source text for Eikon: ID:nGNE7Lz8lt
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease